Literature DB >> 16710101

FDG PET for the assessment of myometrial infiltration in clinical stage I uterine corpus cancer.

Tatsuo Torizuka1, Fumitoshi Nakamura, Munetaka Takekuma, Toshihiko Kanno, Tomomi Ogusu, Etsuji Yoshikawa, Hiroyuki Okada, Makoto Maeda, Yasuomi Ouchi.   

Abstract

OBJECTIVE: For surgical planning of uterine corpus cancer, prior knowledge of the depth of myometrial invasion is important. Curative tumour resection is possible in superficial invasion (stages IA and IB), while post-surgical chemotherapy or radiation therapy is required in deep invasion (stage IC). We evaluated the value of positron emission tomography with 2-[(18)F]fluoro-2-deoxy-D-glucose (FDG PET) for estimating the myometrial invasion in uterine corpus cancer.
METHODS: We studied 22 patients with clinical stage I uterine corpus cancer, who underwent FDG PET prior to surgery. Standardized uptake value (SUV; tracer activity per injected dose normalized to body weight) was calculated on the PET image. PET findings were compared with magnetic resonance imaging (MRI) and the surgical staging.
RESULTS: The surgical stage was IA in five, IB in 11 and IC in six patients. SUVs in deep invasion (15.69+/-4.73, 8.83-21.84) were significantly higher than those in superficial invasion (9.09+/-3.29, 2.68-15.41) (P<0.005). Using 12.0 as a cut-off value of SUV for the differentiation of these two groups, PET results were correct in 19 patients but were incorrect in three patients. Although both PET and MRI provided correct staging in 14 patients, only MRI overestimated the myometrial invasion in four patients with stage IB and showed inconclusive findings in one patient with stage IC. Four of these five patients were post-menopausal.
CONCLUSIONS: The cut-off value of SUV (=12.0) may be a useful index for the differentiation of superficial invasion and deep invasion. FDG PET may be feasible for predicting the myometrial infiltration of uterine corpus cancer, especially when uterine atrophy makes it difficult at MRI in post-menopausal patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710101     DOI: 10.1097/00006231-200606000-00002

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  5 in total

1.  Prognostic significance of SUVmax (maximum standardized uptake value) measured by [¹⁸F]FDG PET/CT in endometrial cancer.

Authors:  Kazuhiro Kitajima; Masato Kita; Kayo Suzuki; Michio Senda; Yuji Nakamoto; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-17       Impact factor: 9.236

2.  Preoperative risk stratification using metabolic parameters of (18)F-FDG PET/CT in patients with endometrial cancer.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Yoshiko Ueno; Tetsuo Maeda; Yasuhiko Ebina; Hideto Yamada; Takashi Okunaga; Kazuhiro Kubo; Keitarou Sofue; Tomonori Kanda; Yukihisa Tamaki; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-02       Impact factor: 9.236

3.  Preoperative PET/CT standardized FDG uptake values of pelvic lymph nodes as a significant prognostic factor in patients with endometrial cancer.

Authors:  Hyun Hoon Chung; Gi Jeong Cheon; Hee Seung Kim; Jae Weon Kim; Noh-Hyun Park; Yong Sang Song
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-29       Impact factor: 9.236

Review 4.  Novel imaging modalities in gynecologic cancer.

Authors:  Rebecca A Brooks; Matthew A Powell
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

5.  The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients.

Authors:  Malgorzata Walentowicz-Sadlecka; Bogdan Malkowski; Pawel Walentowicz; Pawel Sadlecki; Andrzej Marszalek; Tomasz Pietrzak; Marek Grabiec
Journal:  Biomed Res Int       Date:  2014-01-20       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.